Drug Patents owned by Abbvie Inc

1. Drug name - MAVYRET

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8648037 ABBVIE INC Macrocyclic proline derived HCV serine protease inhibitors
Jan, 2032

(9 years from now)

US8937150 ABBVIE INC Anti-viral compounds
May, 2032

(9 years from now)

USRE48923 ABBVIE INC Crystal forms
May, 2035

(12 years from now)

US9321807 ABBVIE INC Crystal forms
Jun, 2035

(12 years from now)

CN103819537A ABBVIE INC Anti-Viral Compounds
May, 2017

(5 years ago)

CN104193729A ABBVIE INC Antiviral Compound
Sep, 2017

(5 years ago)

CN106986861A ABBVIE INC Antiviral Compound
Jun, 2020

(2 years ago)

CN103819459B ABBVIE INC Antiviral Compound
May, 2021

(1 year, 4 months ago)

CN103819459A ABBVIE INC Antiviral Compound
May, 2021

(1 year, 4 months ago)

CN103172620A ABBVIE INC Antiviral Composition
Jun, 2030

(7 years from now)

CN103172620B ABBVIE INC Antiviral Compound
Jun, 2030

(7 years from now)

CN102333772A ABBVIE INC Anti-Viral Compounds
Jun, 2030

(7 years from now)

CN102333772B ABBVIE INC Antiviral Composition
Jun, 2030

(7 years from now)

CN103209686A ABBVIE INC Solid Composition
Jun, 2031

(8 years from now)

CN103209686B ABBVIE INC Solid Composition
Jun, 2031

(8 years from now)

CN103209703A ABBVIE INC Macrocyclic Proline Derived Hcv Serine Protease Inhibitors
Sep, 2031

(8 years from now)

CN104829688A ABBVIE INC Macrocyclic Proline Derived Hcv Serine Protease Inhibitors
Sep, 2031

(8 years from now)

CN104829688B ABBVIE INC Macrocyclic Proline-Derived Hcv Serine Protease Inhibitors
Sep, 2031

(8 years from now)

CN103209703B ABBVIE INC Macrocyclic Proline Derived Hcv Serine Protease Inhibitors
Sep, 2031

(8 years from now)

CN103153988B ABBVIE INC Antiviral Compound
Oct, 2031

(9 years from now)

CN103153988A ABBVIE INC Anti-Viral Compounds
Oct, 2031

(9 years from now)

CN103354808A ABBVIE INC Antiviral Compound
Dec, 2031

(9 years from now)

CN103354808B ABBVIE INC Antiviral Compound
Dec, 2031

(9 years from now)

CN103596941A ABBVIE INC Anti-Viral Compounds
Feb, 2032

(9 years from now)

CN103596941B ABBVIE INC Antiviral Compounds
Feb, 2032

(9 years from now)

CN108350016A ABBVIE INC Antiviral Tetrahydrofuran Derivatives
Sep, 2036

(13 years from now)

CN108350016B ABBVIE INC Antiviral Tetrahydrofuran Derivatives
Sep, 2036

(13 years from now)

EP2954892B1 ABBVIE INC Solid Compositions
Jun, 2020

(2 years ago)

EP2954892A1 ABBVIE INC Solid Compositions
Jun, 2020

(2 years ago)

EP2455376A1 ABBVIE INC Heterocyclic Compounds As Inhibitors Of Hepatitis C Virus (Hcv)
Jun, 2030

(7 years from now)

EP2337781B1 ABBVIE INC Anti-Viral Compounds To Treat Hcv Infection
Jun, 2030

(7 years from now)

EP2628481B1 ABBVIE INC Trisubstituted Heterocycles As Replication Inhibitors Of Hepatitis C Virus Hcv
Jun, 2030

(7 years from now)

EP2628481A1 ABBVIE INC Trisubstituted Heterocycles As Replication Inhibitors Of Hepatitis C Virus Hcv
Jun, 2030

(7 years from now)

EP2337781A2 ABBVIE INC Anti-Viral Compounds To Treat Hcv Infection
Jun, 2030

(7 years from now)

EP2455376B1 ABBVIE INC Heterocyclic Compounds As Inhibitors Of Hepatitis C Virus (Hcv)
Jun, 2030

(7 years from now)

EP2368890B1 ABBVIE INC Hepatitis C Virus Inhibitors
Jun, 2030

(7 years from now)

EP2368890A1 ABBVIE INC Hepatitis C Virus Inhibitors
Jun, 2030

(7 years from now)

EP2368890B9 ABBVIE INC Hepatitis C Virus Inhibitors
Jun, 2030

(7 years from now)

EP2579854B1 ABBVIE INC Solid Compositions
Jun, 2031

(8 years from now)

EP2579854B2 ABBVIE INC Solid Compositions
Jun, 2031

(8 years from now)

EP2579854A1 ABBVIE INC Solid Compositions
Jun, 2031

(8 years from now)

EP2618831B1 ABBVIE INC Macrocyclic Proline Derived Hcv Serine Protease Inhibitors
Sep, 2031

(8 years from now)

EP2618831A1 ABBVIE INC Macrocyclic Proline Derived Hcv Serine Protease Inhibitors
Sep, 2031

(8 years from now)

EP2618831A4 ABBVIE INC Macrocyclic Proline Derived Hcv Serine Protease Inhibitors
Sep, 2031

(8 years from now)

EP2692346A1 ABBVIE INC An Antiviral 1-Phenyl-2,5-Dibenzimidazol-5-Yl-Pyrrolidine Derivative
Oct, 2031

(9 years from now)

EP2692346B1 ABBVIE INC An Antiviral 1-Phenyl-2,5-Dibenzimidazol-5-Yl-Pyrrolidine Derivative
Oct, 2031

(9 years from now)

EP2678334B1 ABBVIE INC Anti-Viral Compounds
Feb, 2032

(9 years from now)

EP2678334A1 ABBVIE INC Anti-Viral Compounds
Feb, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10039754 ABBVIE INC Anti-viral compounds Jun, 2030

(7 years from now)

US10028937 ABBVIE INC Anti-viral compounds Jun, 2030

(7 years from now)

US9586978 ABBVIE INC Anti-viral compounds Nov, 2030

(8 years from now)

US10028937

(Pediatric)

ABBVIE INC Anti-viral compounds Dec, 2030

(8 years from now)

US10039754

(Pediatric)

ABBVIE INC Anti-viral compounds Dec, 2030

(8 years from now)

US9586978

(Pediatric)

ABBVIE INC Anti-viral compounds May, 2031

(8 years from now)

US8648037

(Pediatric)

ABBVIE INC Macrocyclic proline derived HCV serine protease inhibitors Jul, 2032

(9 years from now)

US8937150

(Pediatric)

ABBVIE INC Anti-viral compounds Nov, 2032

(10 years from now)

US10286029 ABBVIE INC Method for treating HCV Mar, 2034

(11 years from now)

US10286029

(Pediatric)

ABBVIE INC Method for treating HCV Sep, 2034

(11 years from now)

USRE48923

(Pediatric)

ABBVIE INC Crystal forms Nov, 2035

(13 years from now)

US9321807

(Pediatric)

ABBVIE INC Crystal forms Dec, 2035

(13 years from now)

US11246866 ABBVIE INC Solid pharmaceutical compositions for treating HCV Jun, 2036

(13 years from now)

US11246866

(Pediatric)

ABBVIE INC Solid pharmaceutical compositions for treating HCV Dec, 2036

(14 years from now)

Drugs and Companies using GLECAPREVIR; PIBRENTASVIR ingredient

Treatment: Treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6 in pediatric patients 3 to less than 12 years of age or weighing less than 45 kg; Treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6; treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6 in adult and pediatric patients 12 years and older or weighing at least 45 kg

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
100MG;40MG TABLET;ORAL Prescription

2. Drug name - ORIAHNN (COPACKAGED)

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7419983 ABBVIE INC Gonadotropin-releasing hormone receptor antagonists and methods related thereto
Jul, 2024

(1 year, 9 months from now)

US7056927 ABBVIE INC Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
Sep, 2024

(1 year, 11 months from now)

CN100424078C ABBVIE INC As Gonadotropin-Releasing Hormone Receptor Antagonists And -2 - 4-Dione Derivatives
Jul, 2024

(1 year, 9 months from now)

CN1819829A ABBVIE INC As Gonadotropin-Releasing Hormone Receptor Antagonists And -2 - 4-Dione Derivatives
Jul, 2024

(1 year, 9 months from now)

IN200600072P1 ABBVIE INC Pyrimidine-2,4-Dione Derivatives As Gonadotropin-Releasing Hormone Receptor Antagonists
Jul, 2024

(1 year, 9 months from now)

IN312234B ABBVIE INC Pyrimidine-2, 4-Dione Based Compounds As Gonadotropin-Releasing Hormone Receptor Antagonists
Jul, 2024

(1 year, 9 months from now)

EP1646389A1 ABBVIE INC Pyrimidine-2,4-Dione Derivatives As Gonadotropin-Releasing Hormone Receptor Antagonists
Jul, 2024

(1 year, 9 months from now)

EP1646389B1 ABBVIE INC Pyrimidine-2,4-Dione Derivatives As Gonadotropin-Releasing Hormone Receptor Antagonists
Jul, 2024

(1 year, 9 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10881659 ABBVIE INC Methods of treating heavy menstrual bleeding Mar, 2034

(11 years from now)

US11045470 ABBVIE INC Methods of treating heavy menstrual bleeding Mar, 2034

(11 years from now)

Drugs and Companies using ELAGOLIX SODIUM,ESTRADIOL,NORETHINDRONE ACETATE; ELAGOLIX SODIUM ingredient

Treatment: Management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids)

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 300MG BASE,1MG,0.5MG; EQ 300MG BASE CAPSULE;ORAL Prescription

3. Drug name - ORILISSA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7419983 ABBVIE INC Gonadotropin-releasing hormone receptor antagonists and methods related thereto
Jul, 2024

(1 year, 9 months from now)

US7056927 ABBVIE INC Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
Sep, 2024

(1 year, 11 months from now)

CN100424078C ABBVIE INC As Gonadotropin-Releasing Hormone Receptor Antagonists And -2 - 4-Dione Derivatives
Jul, 2024

(1 year, 9 months from now)

CN1819829A ABBVIE INC As Gonadotropin-Releasing Hormone Receptor Antagonists And -2 - 4-Dione Derivatives
Jul, 2024

(1 year, 9 months from now)

IN200600072P1 ABBVIE INC Pyrimidine-2,4-Dione Derivatives As Gonadotropin-Releasing Hormone Receptor Antagonists
Jul, 2024

(1 year, 9 months from now)

IN312234B ABBVIE INC Pyrimidine-2, 4-Dione Based Compounds As Gonadotropin-Releasing Hormone Receptor Antagonists
Jul, 2024

(1 year, 9 months from now)

EP1646389A1 ABBVIE INC Pyrimidine-2,4-Dione Derivatives As Gonadotropin-Releasing Hormone Receptor Antagonists
Jul, 2024

(1 year, 9 months from now)

EP1646389B1 ABBVIE INC Pyrimidine-2,4-Dione Derivatives As Gonadotropin-Releasing Hormone Receptor Antagonists
Jul, 2024

(1 year, 9 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7176211 ABBVIE INC Gonadotropin-releasing hormone receptor antagonists and methods relating thereto Jul, 2024

(1 year, 9 months from now)

US10682351 ABBVIE INC Methods of administering elagolix Sep, 2036

(13 years from now)

US10537572 ABBVIE INC Methods of administering elagolix Sep, 2036

(13 years from now)

Drugs and Companies using ELAGOLIX SODIUM ingredient

Treatment: Management of moderate to severe pain associated with endometriosis; Management of moderate to severe pain associated with endometriosis using 150 mg elagolix while co-administering ketoconazole; Management of moderate to severe pain associated with endometriosis using 150mg elagolix while co-administering rifampin

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 150MG BASE TABLET;ORAL Prescription
EQ 200MG BASE TABLET;ORAL Prescription

4. Drug name - QULIPTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9499545 ABBVIE INC Piperidinone carboxamide azaindane CGRP receptor antagonists
Nov, 2031

(9 years from now)

US8754096 ABBVIE INC Piperidinone carboxamide azaindane CGRP receptor antagonists
Jul, 2032

(9 years from now)

US9850246 ABBVIE INC Process for making CGRP receptor antagonists
Mar, 2033

(10 years from now)

CN103328478A ABBVIE INC Piperidones Carboxamide Indane Cgrp Receptor Antagonist
Nov, 2031

(9 years from now)

CN103328478B ABBVIE INC Piperidone Carboxamide Nitrogen Mixed Indene Into Cgrp Receptor Antagonists
Nov, 2031

(9 years from now)

IN201303390P4 ABBVIE INC Piperidinone Carboxamide Azaindane Cgrp Receptor Antagonists
Nov, 2031

(9 years from now)

IN289826B ABBVIE INC Piperidinone Carboxamide Azaindane Cgrp Receptor Antagonists
Nov, 2031

(9 years from now)

EP2821407B1 ABBVIE INC Piperidinone Carboxamide Azaindane Cgrp Receptor Antagonists
Nov, 2031

(9 years from now)

EP2638042A1 ABBVIE INC Piperidinone Carboxamide Azaindane Cgrp Receptor Antagonists
Nov, 2031

(9 years from now)

EP2821407A1 ABBVIE INC Piperidinone Carboxamide Azaindane Cgrp Receptor Antagonists
Nov, 2031

(9 years from now)

EP2638042B1 ABBVIE INC Piperidinone Carboxamide Azaindane Cgrp Receptor Antagonists
Nov, 2031

(9 years from now)

EP2849568B1 ABBVIE INC Process For Making Cgrp Receptor Antagonists
Mar, 2033

(10 years from now)

EP2849568A4 ABBVIE INC Process For Making Cgrp Receptor Antagonists
Mar, 2033

(10 years from now)

EP2849568A1 ABBVIE INC Process For Making Cgrp Receptor Antagonists
Mar, 2033

(10 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10117836 ABBVIE INC Tablet formulation for CGRP active compounds Jan, 2035

(12 years from now)

Drugs and Companies using ATOGEPANT ingredient

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
10MG TABLET;ORAL Prescription
30MG TABLET;ORAL Prescription
60MG TABLET;ORAL Prescription

5. Drug name - RINVOQ

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE47221 ABBVIE INC Tricyclic compounds
Dec, 2030

(8 years from now)

US8962629 ABBVIE INC Tricyclic compounds
Jan, 2031

(8 years from now)

US10981923 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[l,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(14 years from now)

US11186584 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(14 years from now)

US9951080 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-alpha]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(14 years from now)

CN102118968A ABBVIE INC Novel Tricyclic Compounds
Sep, 2015

(7 years ago)

CN104592231A ABBVIE INC Novel Tricyclic Compounds
Jan, 2019

(3 years ago)

CN102711476A ABBVIE INC Novel Tricyclic Compounds
Dec, 2030

(8 years from now)

CN109053742B ABBVIE INC Tricyclic Compounds
Dec, 2030

(8 years from now)

CN104370909A ABBVIE INC Novel Tricyclic Compounds
Dec, 2030

(8 years from now)

CN104370909B ABBVIE INC Tricyclic Compounds
Dec, 2030

(8 years from now)

CN109053742A ABBVIE INC Novel Tricyclic Compounds
Dec, 2030

(8 years from now)

CN102711476B ABBVIE INC Novel Tricyclic Compounds
Dec, 2030

(8 years from now)

IN292307B ABBVIE INC Novel Tricyclic Compounds
Jun, 2029

(6 years from now)

IN201100195P1 ABBVIE INC Novel Tricyclic Compounds
Jun, 2029

(6 years from now)

EP2299821A4 ABBVIE INC Novel Tricyclic Compounds
Jun, 2029

(6 years from now)

EP2299821A1 ABBVIE INC Tricyclic Compounds
Jun, 2029

(6 years from now)

EP2299821B1 ABBVIE INC Tricyclic Compounds
Jun, 2029

(6 years from now)

EP2506716A1 ABBVIE INC Novel Tricyclic Compounds
Dec, 2030

(8 years from now)

EP2506716A4 ABBVIE INC Novel Tricyclic Compounds
Dec, 2030

(8 years from now)

EP2506716B1 ABBVIE INC Novel Tricyclic Compounds
Dec, 2030

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10995095 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carb oxamide and solid state forms thereof Oct, 2036

(14 years from now)

US10344036 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-#a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-#carboxamide and solid state forms thereof Oct, 2036

(14 years from now)

US11198697 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof Oct, 2036

(14 years from now)

US10597400 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carb oxamide and solid state forms thereof Oct, 2036

(14 years from now)

US10519164 ABBVIE INC Processes for the preparation of (3S,4R)-3,ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof Oct, 2036

(14 years from now)

US10981924 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof Oct, 2036

(14 years from now)

US10550126 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof Oct, 2036

(14 years from now)

US9963459 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-alpla]pyrrolo[2,3-e]-pyrazin-8-YL)-N-(2,2,2-Trifluoroethyl)pyrrol and solid state forms thereof Oct, 2036

(14 years from now)

US10730883 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof Oct, 2036

(14 years from now)

Drugs and Companies using UPADACITINIB ingredient

Treatment: Treatment of adults and pediatric patients 12 years of age and older with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, or when use of those therapies are inadvisable; Treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more tnf blockers

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
15MG TABLET, EXTENDED RELEASE;ORAL Prescription
30MG TABLET, EXTENDED RELEASE;ORAL Prescription

6. Drug name - TECHNIVIE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8642538 ABBVIE INC Macrocyclic hepatitis C serine protease inhibitors
Sep, 2029

(6 years from now)

US8420596 ABBVIE INC Macrocyclic hepatitis C serine protease inhibitors
Apr, 2031

(8 years from now)

US8691938 ABBVIE INC Anti-viral compounds
Apr, 2032

(9 years from now)

CN103819537A ABBVIE INC Anti-Viral Compounds
May, 2017

(5 years ago)

CN104193729A ABBVIE INC Antiviral Compound
Sep, 2017

(5 years ago)

CN106986861A ABBVIE INC Antiviral Compound
Jun, 2020

(2 years ago)

CN103819459B ABBVIE INC Antiviral Compound
May, 2021

(1 year, 4 months ago)

CN103819459A ABBVIE INC Antiviral Compound
May, 2021

(1 year, 4 months ago)

CN102641271B ABBVIE INC Macrocyclic Hepatitis C Serine Protease Inhibitors
Aug, 2021

(1 year, 1 month ago)

CN102641271A ABBVIE INC Hepatitis C Serine Protease Inhibitor Of Macrocyclic Compound
Aug, 2021

(1 year, 1 month ago)

CN101775017B ABBVIE INC Macrocyclic Compounds Of Hepatitis C Serine Protease Inhibitors
Sep, 2029

(6 years from now)

CN101775017A ABBVIE INC Macrocyclic Hepatitis C Serine Protease Inhibitors
Sep, 2029

(6 years from now)

CN103172620A ABBVIE INC Antiviral Composition
Jun, 2030

(7 years from now)

CN103172620B ABBVIE INC Antiviral Compound
Jun, 2030

(7 years from now)

CN102333772A ABBVIE INC Anti-Viral Compounds
Jun, 2030

(7 years from now)

CN102333772B ABBVIE INC Antiviral Composition
Jun, 2030

(7 years from now)

CN103209686A ABBVIE INC Solid Composition
Jun, 2031

(8 years from now)

CN103209686B ABBVIE INC Solid Composition
Jun, 2031

(8 years from now)

CN103153988B ABBVIE INC Antiviral Compound
Oct, 2031

(9 years from now)

CN103153988A ABBVIE INC Anti-Viral Compounds
Oct, 2031

(9 years from now)

CN103354808A ABBVIE INC Antiviral Compound
Dec, 2031

(9 years from now)

CN103354808B ABBVIE INC Antiviral Compound
Dec, 2031

(9 years from now)

CN103596941A ABBVIE INC Anti-Viral Compounds
Feb, 2032

(9 years from now)

CN103596941B ABBVIE INC Antiviral Compounds
Feb, 2032

(9 years from now)

CN108350016A ABBVIE INC Antiviral Tetrahydrofuran Derivatives
Sep, 2036

(13 years from now)

CN108350016B ABBVIE INC Antiviral Tetrahydrofuran Derivatives
Sep, 2036

(13 years from now)

IN287227B ABBVIE INC Macrocyclic Hepatitis C Serine Protease Inhibitors
Sep, 2029

(6 years from now)

IN200907222P1 ABBVIE INC Macrocyclic Hepatitis C Serine Protease Inhibitors
Sep, 2029

(6 years from now)

EP2954892B1 ABBVIE INC Solid Compositions
Jun, 2020

(2 years ago)

EP2954892A1 ABBVIE INC Solid Compositions
Jun, 2020

(2 years ago)

EP2468285B1 ABBVIE INC Macrocyclic Hepatitis C Serine Protease Inhibitors
Sep, 2029

(6 years from now)

EP2468285A1 ABBVIE INC Macrocyclic Hepatitis C Serine Protease Inhibitors
Sep, 2029

(6 years from now)

EP2468286A1 ABBVIE INC Macrocyclic Hepatitis C Serine Protease Inhibitors
Sep, 2029

(6 years from now)

EP2805726B1 ABBVIE INC Macrocyclic Hepatitis C Serine Protease Inhibitors
Sep, 2029

(6 years from now)

EP2468287B1 ABBVIE INC Macrocyclic Hepatitis C Serine Protease Inhibitors
Sep, 2029

(6 years from now)

EP2805726A1 ABBVIE INC Macrocyclic Hepatitis C Serine Protease Inhibitors
Sep, 2029

(6 years from now)

EP2468286B1 ABBVIE INC Macrocyclic Hepatitis C Serine Protease Inhibitors
Sep, 2029

(6 years from now)

EP2468287A1 ABBVIE INC Macrocyclic Hepatitis C Serine Protease Inhibitors
Sep, 2029

(6 years from now)

EP2340029A4 ABBVIE INC Macrocyclic Hepatitis C Serine Protease Inhibitors
Jan, 2030

(7 years from now)

EP2340029A2 ABBVIE INC Macrocyclic Hepatitis C Serine Protease Inhibitors
Jan, 2030

(7 years from now)

EP2340029B1 ABBVIE INC Macrocyclic Hepatitis C Serine Protease Inhibitors
Jan, 2030

(7 years from now)

EP2455376A1 ABBVIE INC Heterocyclic Compounds As Inhibitors Of Hepatitis C Virus (Hcv)
Jun, 2030

(7 years from now)

EP2337781B1 ABBVIE INC Anti-Viral Compounds To Treat Hcv Infection
Jun, 2030

(7 years from now)

EP2628481B1 ABBVIE INC Trisubstituted Heterocycles As Replication Inhibitors Of Hepatitis C Virus Hcv
Jun, 2030

(7 years from now)

EP2628481A1 ABBVIE INC Trisubstituted Heterocycles As Replication Inhibitors Of Hepatitis C Virus Hcv
Jun, 2030

(7 years from now)

EP2337781A2 ABBVIE INC Anti-Viral Compounds To Treat Hcv Infection
Jun, 2030

(7 years from now)

EP2455376B1 ABBVIE INC Heterocyclic Compounds As Inhibitors Of Hepatitis C Virus (Hcv)
Jun, 2030

(7 years from now)

EP2368890B1 ABBVIE INC Hepatitis C Virus Inhibitors
Jun, 2030

(7 years from now)

EP2368890A1 ABBVIE INC Hepatitis C Virus Inhibitors
Jun, 2030

(7 years from now)

EP2368890B9 ABBVIE INC Hepatitis C Virus Inhibitors
Jun, 2030

(7 years from now)

EP2579854B1 ABBVIE INC Solid Compositions
Jun, 2031

(8 years from now)

EP2579854B2 ABBVIE INC Solid Compositions
Jun, 2031

(8 years from now)

EP2579854A1 ABBVIE INC Solid Compositions
Jun, 2031

(8 years from now)

EP2692346A1 ABBVIE INC An Antiviral 1-Phenyl-2,5-Dibenzimidazol-5-Yl-Pyrrolidine Derivative
Oct, 2031

(9 years from now)

EP2692346B1 ABBVIE INC An Antiviral 1-Phenyl-2,5-Dibenzimidazol-5-Yl-Pyrrolidine Derivative
Oct, 2031

(9 years from now)

EP2678334B1 ABBVIE INC Anti-Viral Compounds
Feb, 2032

(9 years from now)

EP2678334A1 ABBVIE INC Anti-Viral Compounds
Feb, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8268349 ABBVIE INC Solid pharmaceutical dosage form Aug, 2024

(1 year, 10 months from now)

US8399015 ABBVIE INC Solid pharmaceutical dosage form Aug, 2024

(1 year, 10 months from now)

US8268349

(Pediatric)

ABBVIE INC Solid pharmaceutical dosage form Feb, 2025

(2 years from now)

US8399015

(Pediatric)

ABBVIE INC Solid pharmaceutical dosage form Feb, 2025

(2 years from now)

US9006387 ABBVIE INC Anti-viral compounds Jun, 2030

(7 years from now)

US9044480 ABBVIE INC Compositions and methods for treating HCV Apr, 2031

(8 years from now)

US8686026 ABBVIE INC Solid compositions Jun, 2031

(8 years from now)

US8420596

(Pediatric)

ABBVIE INC Macrocyclic hepatitis C serine protease inhibitors Oct, 2031

(9 years from now)

Drugs and Companies using OMBITASVIR; PARITAPREVIR; RITONAVIR ingredient

Treatment: Treatment of hcv infection using ombitasvir; Treatment of hcv infection using paritaprevir

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
12.5MG;75MG;50MG TABLET;ORAL Discontinued

7. Drug name - VENCLEXTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8546399 ABBVIE INC Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
Jun, 2031

(8 years from now)

US10730873 ABBVIE INC Salts and crystalline forms of an apoptosis-inducing agent
Nov, 2031

(9 years from now)

US8722657 ABBVIE INC Salts and crystalline forms of an apoptosis-inducing agent
Jan, 2032

(9 years from now)

CN103328474A ABBVIE INC Salt And Crystalline Cell Apoptosis Inducing Agent
Apr, 2018

(4 years ago)

CN104906100A ABBVIE INC Cell Procedure Death Inducing Medicine Preparation For Treating Cancer And Immune And Autoimmune Disease
Sep, 2019

(3 years ago)

CN109897038A ABBVIE INC For Programmed Cell Death-Inducing Agent For The Treatment Of Cancer And Immune And Autoimmune Diseases
May, 2030

(7 years from now)

CN102448959B ABBVIE INC Cell Procedure Death Inducing Medicine Preparation For Treating Cancer And Immune And Autoimmune Disease
May, 2030

(7 years from now)

CN102448959A ABBVIE INC Apoptosis-Inducing Agents For Treatment Of Cancer And Immune And Autoimmune Diseases
May, 2030

(7 years from now)

CN104876927B ABBVIE INC A Programmed Cell Death Inducing Agent For The Treatment Of Cancer And Immune And Autoimmune Diseases
May, 2030

(7 years from now)

CN104876927A ABBVIE INC For The Treatment Of Cancer And Immune And Autoimmune Diseases Of Programmed Cell Death Inducing Agent
May, 2030

(7 years from now)

CN109897038B ABBVIE INC Cell Programmed Death-Inducing Agent For The Treatment Of Cancer And Immune And Autoimmune Diseases
May, 2030

(7 years from now)

CN103153993B ABBVIE INC Cell Procedure Disease Death Inducing Agent For Treating Cancer And Immune And Autoimmune
Nov, 2030

(8 years from now)

CN103153993A ABBVIE INC Cell Procedure Disease Death Inducing Agent For Treating Cancer And Immune And Autoimmune
Nov, 2030

(8 years from now)

EP2435432B1 ABBVIE INC Apoptosis-Inducing Agents For The Treatment Of Cancer And Immune And Autoimmune Diseases
May, 2030

(7 years from now)

EP2435432A2 ABBVIE INC Apoptosis-Inducing Agents For The Treatment Of Cancer And Immune And Autoimmune Diseases
May, 2030

(7 years from now)

EP2576546A1 ABBVIE INC Apoptosis-Inducing Agents For The Treatment Of Cancer And Immune And Autoimmune Diseases
Nov, 2030

(8 years from now)

EP2576546B1 ABBVIE INC Apoptosis-Inducing Agents For The Treatment Of Cancer And Immune And Autoimmune Diseases
Nov, 2030

(8 years from now)

EP2643322A1 ABBVIE INC Salts And Crystalline Forms Of An Apoptosis-Inducing Agent
Nov, 2031

(9 years from now)

EP2643322B1 ABBVIE INC Salts And Crystalline Forms Of An Apoptosis-Inducing Agent
Nov, 2031

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9174982 ABBVIE INC Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases May, 2030

(7 years from now)

US9539251 ABBVIE INC Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor Sep, 2033

(10 years from now)

US11110087 ABBVIE INC Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor Sep, 2033

(10 years from now)

US10993942 ABBVIE INC Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor Sep, 2033

(10 years from now)

Drugs and Companies using VENETOCLAX ingredient

Treatment: Treatment of adult patients with chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll); treatment in combination with azacitidine or decitabine or low-dose cytarabine of newly-diagnosed acute myeloid leukemia (aml) in adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy; treatment of patients with chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll), with or without 17p deletion, who have received at least one prior therapy; treatment of adult patients with chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll), with or without 17p deletion, who have received at least one prior therapy; Treatment of adult patients with chronic lymphocytic leukemia (cll) or small lymphocytic leukemia (sll) in combination with a ga101 antibody such as obinutuzumab for one or more dosing periods, wherein the cll or sll is a cd20-expressing cancer; Treatment of acute myeloid leukemia (aml) by orally administering venetoclax with azacitidine or decitabine or low-dose cytarabine in adults 75 years or older or having certain comorbidities according to a dose ramp-up including a 100 mg per day dose; treatment of chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll) by orally administering venetoclax to an adult according to a dose ramp-up including a 100 mg per day dose; Treatment of chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll) by orally administering venetoclax to an adult according to a dose ramp-up that includes a dose of 50 mg per day for 1 week followed by 100 mg per day for 1 week

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
10MG TABLET;ORAL Prescription
50MG TABLET;ORAL Prescription
100MG TABLET;ORAL Prescription

8. Drug name - VIEKIRA PAK (COPACKAGED)

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8501238 ABBVIE INC Anti-infective agents and uses thereof
Sep, 2028

(5 years from now)

US8188104 ABBVIE INC Anti-infective agents and uses thereof
May, 2029

(6 years from now)

US8642538 ABBVIE INC Macrocyclic hepatitis C serine protease inhibitors
Sep, 2029

(6 years from now)

US8420596 ABBVIE INC Macrocyclic hepatitis C serine protease inhibitors
Apr, 2031

(8 years from now)

US8691938 ABBVIE INC Anti-viral compounds
Apr, 2032

(9 years from now)

CN103819537A ABBVIE INC Anti-Viral Compounds
May, 2017

(5 years ago)

CN104628655A ABBVIE INC Anti-Infection Pyridine And Application Thereof
Jul, 2017

(5 years ago)

CN104193729A ABBVIE INC Antiviral Compound
Sep, 2017

(5 years ago)

CN104628654A ABBVIE INC Anti-Infection Pyridine And Application Thereof
Oct, 2017

(4 years ago)

CN106986861A ABBVIE INC Antiviral Compound
Jun, 2020

(2 years ago)

CN103819459B ABBVIE INC Antiviral Compound
May, 2021

(1 year, 4 months ago)

CN103819459A ABBVIE INC Antiviral Compound
May, 2021

(1 year, 4 months ago)

CN102641271B ABBVIE INC Macrocyclic Hepatitis C Serine Protease Inhibitors
Aug, 2021

(1 year, 1 month ago)

CN102641271A ABBVIE INC Hepatitis C Serine Protease Inhibitor Of Macrocyclic Compound
Aug, 2021

(1 year, 1 month ago)

CN102746240A ABBVIE INC Anti-Infective Pyrimidines And Uses Thereof
Aug, 2021

(1 year, 1 month ago)

CN102746240B ABBVIE INC Anti-Infective Pyrimidines And Uses Thereof
Aug, 2021

(1 year, 1 month ago)

CN101842360B ABBVIE INC Anti-Infection Pyridine And Application Thereof
Sep, 2028

(5 years from now)

CN101842360A ABBVIE INC Anti-Infective Pyrimidines And Uses Thereof
Sep, 2028

(5 years from now)

CN101775017B ABBVIE INC Macrocyclic Compounds Of Hepatitis C Serine Protease Inhibitors
Sep, 2029

(6 years from now)

CN101775017A ABBVIE INC Macrocyclic Hepatitis C Serine Protease Inhibitors
Sep, 2029

(6 years from now)

CN103172620A ABBVIE INC Antiviral Composition
Jun, 2030

(7 years from now)

CN103172620B ABBVIE INC Antiviral Compound
Jun, 2030

(7 years from now)

CN102333772A ABBVIE INC Anti-Viral Compounds
Jun, 2030

(7 years from now)

CN102333772B ABBVIE INC Antiviral Composition
Jun, 2030

(7 years from now)

CN103209686A ABBVIE INC Solid Composition
Jun, 2031

(8 years from now)

CN103209686B ABBVIE INC Solid Composition
Jun, 2031

(8 years from now)

CN103153988B ABBVIE INC Antiviral Compound
Oct, 2031

(9 years from now)

CN103153988A ABBVIE INC Anti-Viral Compounds
Oct, 2031

(9 years from now)

CN103354808A ABBVIE INC Antiviral Compound
Dec, 2031

(9 years from now)

CN103354808B ABBVIE INC Antiviral Compound
Dec, 2031

(9 years from now)

CN103596941A ABBVIE INC Anti-Viral Compounds
Feb, 2032

(9 years from now)

CN103596941B ABBVIE INC Antiviral Compounds
Feb, 2032

(9 years from now)

CN108350016A ABBVIE INC Antiviral Tetrahydrofuran Derivatives
Sep, 2036

(13 years from now)

CN108350016B ABBVIE INC Antiviral Tetrahydrofuran Derivatives
Sep, 2036

(13 years from now)

IN287227B ABBVIE INC Macrocyclic Hepatitis C Serine Protease Inhibitors
Sep, 2029

(6 years from now)

IN200907222P1 ABBVIE INC Macrocyclic Hepatitis C Serine Protease Inhibitors
Sep, 2029

(6 years from now)

EP2954892B1 ABBVIE INC Solid Compositions
Jun, 2020

(2 years ago)

EP2954892A1 ABBVIE INC Solid Compositions
Jun, 2020

(2 years ago)

EP2639226B1 ABBVIE INC Anti-Infective Pyrimidines And Uses Thereof
Sep, 2028

(5 years from now)

EP2368882B1 ABBVIE INC Anti-Infective Pyrimidines And Uses Thereof
Sep, 2028

(5 years from now)

EP2639226A1 ABBVIE INC Anti-Infective Pyrimidines And Uses Thereof
Sep, 2028

(5 years from now)

EP2368882A1 ABBVIE INC Anti-Infective Pyrimidines And Uses Thereof
Sep, 2028

(5 years from now)

EP2468285B1 ABBVIE INC Macrocyclic Hepatitis C Serine Protease Inhibitors
Sep, 2029

(6 years from now)

EP2468285A1 ABBVIE INC Macrocyclic Hepatitis C Serine Protease Inhibitors
Sep, 2029

(6 years from now)

EP2468286A1 ABBVIE INC Macrocyclic Hepatitis C Serine Protease Inhibitors
Sep, 2029

(6 years from now)

EP2805726B1 ABBVIE INC Macrocyclic Hepatitis C Serine Protease Inhibitors
Sep, 2029

(6 years from now)

EP2468287B1 ABBVIE INC Macrocyclic Hepatitis C Serine Protease Inhibitors
Sep, 2029

(6 years from now)

EP2805726A1 ABBVIE INC Macrocyclic Hepatitis C Serine Protease Inhibitors
Sep, 2029

(6 years from now)

EP2468286B1 ABBVIE INC Macrocyclic Hepatitis C Serine Protease Inhibitors
Sep, 2029

(6 years from now)

EP2468287A1 ABBVIE INC Macrocyclic Hepatitis C Serine Protease Inhibitors
Sep, 2029

(6 years from now)

EP2340029A4 ABBVIE INC Macrocyclic Hepatitis C Serine Protease Inhibitors
Jan, 2030

(7 years from now)

EP2340029A2 ABBVIE INC Macrocyclic Hepatitis C Serine Protease Inhibitors
Jan, 2030

(7 years from now)

EP2203431B1 ABBVIE INC Anti-Infective Pyrimidines And Uses Thereof
Jan, 2030

(7 years from now)

EP2203431A1 ABBVIE INC Anti-Infective Pyrimidines And Uses Thereof
Jan, 2030

(7 years from now)

EP2340029B1 ABBVIE INC Macrocyclic Hepatitis C Serine Protease Inhibitors
Jan, 2030

(7 years from now)

EP2455376A1 ABBVIE INC Heterocyclic Compounds As Inhibitors Of Hepatitis C Virus (Hcv)
Jun, 2030

(7 years from now)

EP2337781B1 ABBVIE INC Anti-Viral Compounds To Treat Hcv Infection
Jun, 2030

(7 years from now)

EP2628481B1 ABBVIE INC Trisubstituted Heterocycles As Replication Inhibitors Of Hepatitis C Virus Hcv
Jun, 2030

(7 years from now)

EP2628481A1 ABBVIE INC Trisubstituted Heterocycles As Replication Inhibitors Of Hepatitis C Virus Hcv
Jun, 2030

(7 years from now)

EP2337781A2 ABBVIE INC Anti-Viral Compounds To Treat Hcv Infection
Jun, 2030

(7 years from now)

EP2455376B1 ABBVIE INC Heterocyclic Compounds As Inhibitors Of Hepatitis C Virus (Hcv)
Jun, 2030

(7 years from now)

EP2368890B1 ABBVIE INC Hepatitis C Virus Inhibitors
Jun, 2030

(7 years from now)

EP2368890A1 ABBVIE INC Hepatitis C Virus Inhibitors
Jun, 2030

(7 years from now)

EP2368890B9 ABBVIE INC Hepatitis C Virus Inhibitors
Jun, 2030

(7 years from now)

EP2579854B1 ABBVIE INC Solid Compositions
Jun, 2031

(8 years from now)

EP2579854B2 ABBVIE INC Solid Compositions
Jun, 2031

(8 years from now)

EP2579854A1 ABBVIE INC Solid Compositions
Jun, 2031

(8 years from now)

EP2692346A1 ABBVIE INC An Antiviral 1-Phenyl-2,5-Dibenzimidazol-5-Yl-Pyrrolidine Derivative
Oct, 2031

(9 years from now)

EP2692346B1 ABBVIE INC An Antiviral 1-Phenyl-2,5-Dibenzimidazol-5-Yl-Pyrrolidine Derivative
Oct, 2031

(9 years from now)

EP2678334B1 ABBVIE INC Anti-Viral Compounds
Feb, 2032

(9 years from now)

EP2678334A1 ABBVIE INC Anti-Viral Compounds
Feb, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8268349 ABBVIE INC Solid pharmaceutical dosage form Aug, 2024

(1 year, 10 months from now)

US8399015 ABBVIE INC Solid pharmaceutical dosage form Aug, 2024

(1 year, 10 months from now)

US9139536 ABBVIE INC Anti-infective agents and uses thereof Nov, 2028

(6 years from now)

US9006387 ABBVIE INC Anti-viral compounds Jun, 2030

(7 years from now)

US9044480 ABBVIE INC Compositions and methods for treating HCV Apr, 2031

(8 years from now)

US8686026 ABBVIE INC Solid compositions Jun, 2031

(8 years from now)

US8466159 ABBVIE INC Methods for treating HCV Sep, 2032

(9 years from now)

US8492386 ABBVIE INC Methods for treating HCV Sep, 2032

(9 years from now)

US8685984 ABBVIE INC Methods for treating HCV Sep, 2032

(9 years from now)

US8680106 ABBVIE INC Methods for treating HCV Sep, 2032

(9 years from now)

US9629841 ABBVIE INC Formulations of pyrimidinedione derivative compounds Oct, 2033

(11 years from now)

US10201542 ABBVIE INC Formulations of pyrimidinedione derivative compounds Oct, 2033

(11 years from now)

Drugs and Companies using DASABUVIR SODIUM; OMBITASVIR, PARITAPREVIR, RITONAVIR ingredient

Treatment: Treatment of hcv infection using dasabuvir; Treatment of hcv infection using ombitasvir; Treatment of hcv infection using paritaprevir; Treatment of hcv infection using paritaprevir, ombitasvir, ritonavir, and dasabuvir with ribavirin.; Treatment of hcv infection using paritaprevir, ombitasvir, ritonavir, and dasabuvir, without ribavirin

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 250MG BASE;12.5MG, 75MG, 50MG TABLET;ORAL Discontinued

9. Drug name - VIEKIRA XR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8501238 ABBVIE INC Anti-infective agents and uses thereof
Sep, 2028

(5 years from now)

US8188104 ABBVIE INC Anti-infective agents and uses thereof
May, 2029

(6 years from now)

US8642538 ABBVIE INC Macrocyclic hepatitis C serine protease inhibitors
Sep, 2029

(6 years from now)

US8420596 ABBVIE INC Macrocyclic hepatitis C serine protease inhibitors
Apr, 2031

(8 years from now)

US8691938 ABBVIE INC Anti-viral compounds
Apr, 2032

(9 years from now)

CN103819537A ABBVIE INC Anti-Viral Compounds
May, 2017

(5 years ago)

CN104628655A ABBVIE INC Anti-Infection Pyridine And Application Thereof
Jul, 2017

(5 years ago)

CN104193729A ABBVIE INC Antiviral Compound
Sep, 2017

(5 years ago)

CN104628654A ABBVIE INC Anti-Infection Pyridine And Application Thereof
Oct, 2017

(4 years ago)

CN106986861A ABBVIE INC Antiviral Compound
Jun, 2020

(2 years ago)

CN103819459B ABBVIE INC Antiviral Compound
May, 2021

(1 year, 4 months ago)

CN103819459A ABBVIE INC Antiviral Compound
May, 2021

(1 year, 4 months ago)

CN102641271B ABBVIE INC Macrocyclic Hepatitis C Serine Protease Inhibitors
Aug, 2021

(1 year, 1 month ago)

CN102641271A ABBVIE INC Hepatitis C Serine Protease Inhibitor Of Macrocyclic Compound
Aug, 2021

(1 year, 1 month ago)

CN102746240A ABBVIE INC Anti-Infective Pyrimidines And Uses Thereof
Aug, 2021

(1 year, 1 month ago)

CN102746240B ABBVIE INC Anti-Infective Pyrimidines And Uses Thereof
Aug, 2021

(1 year, 1 month ago)

CN101842360B ABBVIE INC Anti-Infection Pyridine And Application Thereof
Sep, 2028

(5 years from now)

CN101842360A ABBVIE INC Anti-Infective Pyrimidines And Uses Thereof
Sep, 2028

(5 years from now)

CN101775017B ABBVIE INC Macrocyclic Compounds Of Hepatitis C Serine Protease Inhibitors
Sep, 2029

(6 years from now)

CN101775017A ABBVIE INC Macrocyclic Hepatitis C Serine Protease Inhibitors
Sep, 2029

(6 years from now)

CN103172620A ABBVIE INC Antiviral Composition
Jun, 2030

(7 years from now)

CN103172620B ABBVIE INC Antiviral Compound
Jun, 2030

(7 years from now)

CN102333772A ABBVIE INC Anti-Viral Compounds
Jun, 2030

(7 years from now)

CN102333772B ABBVIE INC Antiviral Composition
Jun, 2030

(7 years from now)

CN103209686A ABBVIE INC Solid Composition
Jun, 2031

(8 years from now)

CN103209686B ABBVIE INC Solid Composition
Jun, 2031

(8 years from now)

CN103153988B ABBVIE INC Antiviral Compound
Oct, 2031

(9 years from now)

CN103153988A ABBVIE INC Anti-Viral Compounds
Oct, 2031

(9 years from now)

CN103354808A ABBVIE INC Antiviral Compound
Dec, 2031

(9 years from now)

CN103354808B ABBVIE INC Antiviral Compound
Dec, 2031

(9 years from now)

CN103596941A ABBVIE INC Anti-Viral Compounds
Feb, 2032

(9 years from now)

CN103596941B ABBVIE INC Antiviral Compounds
Feb, 2032

(9 years from now)

CN108350016A ABBVIE INC Antiviral Tetrahydrofuran Derivatives
Sep, 2036

(13 years from now)

CN108350016B ABBVIE INC Antiviral Tetrahydrofuran Derivatives
Sep, 2036

(13 years from now)

IN287227B ABBVIE INC Macrocyclic Hepatitis C Serine Protease Inhibitors
Sep, 2029

(6 years from now)

IN200907222P1 ABBVIE INC Macrocyclic Hepatitis C Serine Protease Inhibitors
Sep, 2029

(6 years from now)

EP2954892B1 ABBVIE INC Solid Compositions
Jun, 2020

(2 years ago)

EP2954892A1 ABBVIE INC Solid Compositions
Jun, 2020

(2 years ago)

EP2639226B1 ABBVIE INC Anti-Infective Pyrimidines And Uses Thereof
Sep, 2028

(5 years from now)

EP2368882B1 ABBVIE INC Anti-Infective Pyrimidines And Uses Thereof
Sep, 2028

(5 years from now)

EP2639226A1 ABBVIE INC Anti-Infective Pyrimidines And Uses Thereof
Sep, 2028

(5 years from now)

EP2368882A1 ABBVIE INC Anti-Infective Pyrimidines And Uses Thereof
Sep, 2028

(5 years from now)

EP2468285B1 ABBVIE INC Macrocyclic Hepatitis C Serine Protease Inhibitors
Sep, 2029

(6 years from now)

EP2468285A1 ABBVIE INC Macrocyclic Hepatitis C Serine Protease Inhibitors
Sep, 2029

(6 years from now)

EP2468286A1 ABBVIE INC Macrocyclic Hepatitis C Serine Protease Inhibitors
Sep, 2029

(6 years from now)

EP2805726B1 ABBVIE INC Macrocyclic Hepatitis C Serine Protease Inhibitors
Sep, 2029

(6 years from now)

EP2468287B1 ABBVIE INC Macrocyclic Hepatitis C Serine Protease Inhibitors
Sep, 2029

(6 years from now)

EP2805726A1 ABBVIE INC Macrocyclic Hepatitis C Serine Protease Inhibitors
Sep, 2029

(6 years from now)

EP2468286B1 ABBVIE INC Macrocyclic Hepatitis C Serine Protease Inhibitors
Sep, 2029

(6 years from now)

EP2468287A1 ABBVIE INC Macrocyclic Hepatitis C Serine Protease Inhibitors
Sep, 2029

(6 years from now)

EP2340029A4 ABBVIE INC Macrocyclic Hepatitis C Serine Protease Inhibitors
Jan, 2030

(7 years from now)

EP2340029A2 ABBVIE INC Macrocyclic Hepatitis C Serine Protease Inhibitors
Jan, 2030

(7 years from now)

EP2203431B1 ABBVIE INC Anti-Infective Pyrimidines And Uses Thereof
Jan, 2030

(7 years from now)

EP2203431A1 ABBVIE INC Anti-Infective Pyrimidines And Uses Thereof
Jan, 2030

(7 years from now)

EP2340029B1 ABBVIE INC Macrocyclic Hepatitis C Serine Protease Inhibitors
Jan, 2030

(7 years from now)

EP2455376A1 ABBVIE INC Heterocyclic Compounds As Inhibitors Of Hepatitis C Virus (Hcv)
Jun, 2030

(7 years from now)

EP2337781B1 ABBVIE INC Anti-Viral Compounds To Treat Hcv Infection
Jun, 2030

(7 years from now)

EP2628481B1 ABBVIE INC Trisubstituted Heterocycles As Replication Inhibitors Of Hepatitis C Virus Hcv
Jun, 2030

(7 years from now)

EP2628481A1 ABBVIE INC Trisubstituted Heterocycles As Replication Inhibitors Of Hepatitis C Virus Hcv
Jun, 2030

(7 years from now)

EP2337781A2 ABBVIE INC Anti-Viral Compounds To Treat Hcv Infection
Jun, 2030

(7 years from now)

EP2455376B1 ABBVIE INC Heterocyclic Compounds As Inhibitors Of Hepatitis C Virus (Hcv)
Jun, 2030

(7 years from now)

EP2368890B1 ABBVIE INC Hepatitis C Virus Inhibitors
Jun, 2030

(7 years from now)

EP2368890A1 ABBVIE INC Hepatitis C Virus Inhibitors
Jun, 2030

(7 years from now)

EP2368890B9 ABBVIE INC Hepatitis C Virus Inhibitors
Jun, 2030

(7 years from now)

EP2579854B1 ABBVIE INC Solid Compositions
Jun, 2031

(8 years from now)

EP2579854B2 ABBVIE INC Solid Compositions
Jun, 2031

(8 years from now)

EP2579854A1 ABBVIE INC Solid Compositions
Jun, 2031

(8 years from now)

EP2692346A1 ABBVIE INC An Antiviral 1-Phenyl-2,5-Dibenzimidazol-5-Yl-Pyrrolidine Derivative
Oct, 2031

(9 years from now)

EP2692346B1 ABBVIE INC An Antiviral 1-Phenyl-2,5-Dibenzimidazol-5-Yl-Pyrrolidine Derivative
Oct, 2031

(9 years from now)

EP2678334B1 ABBVIE INC Anti-Viral Compounds
Feb, 2032

(9 years from now)

EP2678334A1 ABBVIE INC Anti-Viral Compounds
Feb, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8268349 ABBVIE INC Solid pharmaceutical dosage form Aug, 2024

(1 year, 10 months from now)

US8399015 ABBVIE INC Solid pharmaceutical dosage form Aug, 2024

(1 year, 10 months from now)

US9139536 ABBVIE INC Anti-infective agents and uses thereof Nov, 2028

(6 years from now)

US9006387 ABBVIE INC Anti-viral compounds Jun, 2030

(7 years from now)

US9044480 ABBVIE INC Compositions and methods for treating HCV Apr, 2031

(8 years from now)

US8686026 ABBVIE INC Solid compositions Jun, 2031

(8 years from now)

US10201541 ABBVIE INC Compositions and methods for treating HCV May, 2032

(9 years from now)

US10201584 ABBVIE INC Compositions and methods for treating HCV May, 2032

(9 years from now)

US8466159 ABBVIE INC Methods for treating HCV Sep, 2032

(9 years from now)

US8680106 ABBVIE INC Methods for treating HCV Sep, 2032

(9 years from now)

US8492386 ABBVIE INC Methods for treating HCV Sep, 2032

(9 years from now)

US8685984 ABBVIE INC Methods for treating HCV Sep, 2032

(9 years from now)

US9333204 ABBVIE INC Solid antiviral dosage forms Jan, 2035

(12 years from now)

US9744170 ABBVIE INC Solid antiviral dosage forms Jan, 2035

(12 years from now)

US10105365 ABBVIE INC Solid antiviral dosage forms Jan, 2035

(12 years from now)

Drugs and Companies using DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR ingredient

Treatment: Treatment of hcv infection using dasabuvir; Treatment of hcv infection using ombitasvir; Treatment of hcv infection using paritaprevir; Treatment of hcv infection using dasabuvir/ombitasvir/paritaprevir/ritonavir fixed dose combination; Treatment of hcv infection using paritaprevir, ombitasvir, ritonavir, and dasabuvir with ribavirin.; Treatment of hcv infection using paritaprevir, ombitasvir, ritonavir, and dasabuvir, without ribavirin

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 200MG BASE;8.33MG;50MG;33.33MG TABLET, EXTENDED RELEASE;ORAL Discontinued

10. Drug name - VUITY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10610518 ABBVIE INC Presbyopia treatments Apr, 2039

(16 years from now)

Drugs and Companies using PILOCARPINE HYDROCHLORIDE ingredient

Treatment: Use of vuity for the treatment of presbyopia in adults

Dosage: SOLUTION;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
1.25% SOLUTION;OPHTHALMIC Prescription

availability in other generic markets.

Click on the highlighted region to filter.